Prevention of thrombosis with recombinant hirudin in patients with heparin-induced thrombocytopenia type II: A pilot study;Thromboseprophylaxe mittels subkutanem rekombinantem hirudin bei heparin-induzierter thrombozytopenie typ II: Eine pilotstudie

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 22, 2000, Pages 686-691

  Huhle, G ^a   Hoffmann, U ^a   Hoffmann, I ^a   Harenberg, J ^a   Heene, D L ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN;

AGED; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0034595772     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024437     Document Type: Article

References (27)

1. Amiral J, Bridey F, Dreyfus M et al et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost 1992; 68: 95-96
2. Amiral J, Marfaing-Koka A, Wolf M et al et al. Presence of aunoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-induced thrombocytopenia. Blood 1996; 88: 410-416
3. Chong BH, Castaldi PA, Berndt MC. Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and Fc fragments on antibody-heparin-platelet interaction. Thromb Res 1989; 55: 291-295
4. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-589
5. Denomme GA, Warkentin TE, Horsewood P et al et al. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the FcγRIIa 'low responder' (His 131) gene in patients with heparin-induced thrombocytopenia and thrombosis. J Lab Clin Med 1997; 130: 278-284
6. Dodt J, Mueller HP, Seemueller U, Chang JY. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett 1984; 165: 180-184
7. Eriksson BI, Ekman S, Kaelebo P et al et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, DESIRUDIN. Lancet 1996; 347: 635-639
8. Eriksson BI, Wille-Jørgensen P, Kälebo P et al et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335
9. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736
10. Greinacher A, Voelpel H, Janssens U et al et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80
11. Greinacher A, Janssens U, Berg G et al for the heparin-associated thrombocytopenia (HAT) investigators. Lepirudin (Recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587-593
12. Harenberg J, Huhle G, Piazolo L et al et al. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997; 23: 189-196
13. Märki WE, Grossenbacher H, Grütter MG et al et al. Recombinant hirudin: genetic engineering and structure analysis. Sem Thromb Hemost 1991; 17: 88-93
14. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
15. Nowak G und Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202
16. Ortel TL und Chong BH. New treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998; 35: 26-34
17. Parent F, Bridey F, Dreyfus M et al et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 386-388
18. Schiele F, Vuillemenot A, Kramarz P et al et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-562
19. Schiele F, Lindgaerde F, Eriksson H et al for the International Multicentre Hirudin Study Group. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. Thromb Haemost 1997; 77: 834-838
20. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
21. Vermeylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 420-426
22. Wallis RB. From leeches to man. Sem Thromb Hemost 1996; 22: 185-196
23. Wang LC, Huhle G, Hoffmann U et al et al. Heparin-induced thrombocytopenia: New methods for determination, diagnosis and pathophysiology. Clin Lab 1998; 44: 771-780
24. Wang LC, Huhle G, Malsch R et al et al. Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). J Immunol Meth 1999; 222: 93-99
25. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis, Frequency, Avoidance and Management. Drug Safety 1997; 17: 325-334
26. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998; 35: 17-25
27. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the managment of heparin-induced thrombocytopenia. Drugs 1997; 54 (6): 903-924